<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <script src='echarts.min-4.8.0.js'></script>
        <script src='echarts-wordcloud.min.js'></script>
    </head>
    <body>
        <style>
            html, body, #main {
                width: 100%;
                height: 100%;
                margin: 0;
            }
        </style>
        <div id='main'></div>
        <script>
            var chart = echarts.init(document.getElementById('main'));
            var keywords = {"Thyroid gland":2,
"Thyroid neoplasms":5,
"Thyroidectomy":7,
"Epithelial–mesenchymal transition":1,
"Gastric cancer":3,
"Metastatic lymph nodes":1,
"Snail switch":1,
"BRAF mutation":1,
"Iodine":2,
"Papillary thyroid cancer":13,
"Body mass index":1,
"Câncer diferenciado de tireoide":1,
"Differentiated thyroid cancers":2,
"Disease free survival":1,
"Overall survival":1,
"Sobrevida global":1,
"Sobrevida livre de doença":1,
"Índice de massa corporal":1,
"Clinical trials":1,
"Equipoise":1,
"Ethics":1,
"Non-intervention":1,
"Research ethics":1,
"Thyroid cancer":28,
"Active surveillance":2,
"High-risk":1,
"Low-risk":1,
"Observation":1,
"Papillary microcarcinoma":1,
"Thyroid":15,
"American Thyroid Association":1,
"De-escalation":2,
"Guidelines":1,
"Well-differentiated thyroid carcinoma":1,
"ACTH = adrenocorticotropic hormone":1,
"CSDH = chronic subdural hematoma":1,
"DI = diabetes insipidus":1,
"FSH = follicle-stimulating hormone":1,
"GH = growth hormone":1,
"GTR = gross-total resection":1,
"ICA = internal carotid artery":1,
"LH = luteinizing hormone":1,
"NFPA = nonfunctional pituitary adenoma":1,
"NTR = near-total resection":1,
"SKA = supraorbital keyhole approach":1,
"TCA = transcranial approach":1,
"TSA = transsphenoidal approach":1,
"TSH = thyroid-stimulating hormone":1,
"combined approach":1,
"craniopharyngioma":2,
"eSKA = endoscopic SKA":1,
"eTSA = endoscopic TSA":1,
"keyhole":1,
"oncology":3,
"pituitary adenoma":2,
"supraorbital approach":1,
"transsphenoidal approach":1,
"Carcinoma":3,
"Medullary":2,
"Parafollicular C-cells":1,
"Thyroglossal":1,
"ATA Guidelines":1,
"Radioactive iodine":1,
"Micro-papillary thyroid cancer":1,
"Multifocal papillary":1,
"Recurrence free survival":1,
"Tumor recurrence":1,
"Colorectal cancer":1,
"Juvenile polyposis syndrome":1,
"Extensive vascular invasion":1,
"Extrathyroidal extension":2,
"Hurthle cell carcinoma":1,
"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)":1,
"Poorly differentiated thyroid carcinoma":3,
"Bethesda system":2,
"fine needle aspiration":1,
"non-diagnostic":1,
"High intensity focused ultrasound (HIFU)":1,
"Thermal ablation":2,
"Thyroid nodules":7,
"Cancer":7,
"Lymph node":2,
"Metastasis":9,
"Papillary":1,
"SOX11":1,
"in vivo experiments":1,
"miR-211-5p":1,
"thyroid cancer (TC)":1,
"Follicular thyroid carcinoma":4,
"Metastatic thyroid carcinoma":1,
"Molecular signatures of thyroid carcinoma":1,
"Papillary thyroid carcinoma":15,
"Synchronous thyroid carcinomas":1,
"Cost-effectiveness":1,
"Epidemiology":3,
"Recurrence":5,
"Surgery":1,
"Survival":5,
"Thyroid neoplasm":7,
"Anaplastic thyroid carcinoma":4,
"Medullary thyroid carcinoma":5,
"microRNA":3,
"Palladia":1,
"canine":1,
"carboplatin":1,
"dogs":1,
"phase I":1,
"toceranib phosphate":1,
"Age":1,
"Differentiated thyroid cancer":5,
"Ethnic background":1,
"Extrathyroid extension":1,
"Grade":1,
"Invasion":3,
"Lymph node metastasis":6,
"Prognostic markers":1,
"Radioactive iodine avidity":1,
"Size":1,
"Stratification":1,
"Thyroglobulin":3,
"CME":1,
"Colon cancer":2,
"Complete mesocolic excision":1,
"Laparoscopy":1,
"Mesofascial separation":1,
"children":2,
"fine-needle aspiration":6,
"head and neck":1,
"pediatrics":1,
"sonography":1,
"thymus":1,
"thyroid nodule":8,
"thyroid/parathyroid":4,
"Case-control study":1,
"Haplogroup K":1,
"mtDNA haplogroups":1,
"Combined technique":1,
"Lymph node metastases":2,
"Lymphoscintigraphy":1,
"Patent blue injection":1,
"Sentinel lymph node":1,
"Autoimmune thyroiditis":1,
"Normoechogenic thyroid background":1,
"Normoechogenic thyroid parenchyma":1,
"aTG":1,
"aTPO":1,
"fine-needle cytologic examination":1,
"follicular variant of papillary thyroid carcinoma":1,
"ultrasound":4,
"High intensity focused ultrasound":1,
"Microwave ablation":1,
"Radiofrequency ablation":1,
"driver mutations":1,
"lung adenocarcinoma":2,
"psammoma bodies":1,
"shear wave elastography":3,
"ultrasonography":4,
"ultrasound techniques/physics":1,
"BRAF V600E":1,
"NIFTP":5,
"RAS mutations":2,
"thyroid carcinoma":6,
"Behçet disease":1,
"hazard ratio":1,
"incidence":5,
"lymphoma":1,
"myeloid neoplasm radioactive treatment":1,
"Thyroid Imaging Reporting and Data System":1,
"Virtual Touch tissue imaging quantification":1,
"elastography":2,
"Molecular pathology":1,
"Neck dissection":1,
"Prophylactic surgical procedures":1,
"Risk assessment":1,
"EIF1AX":1,
"FNA":1,
"Hürthle cell carcinoma":2,
"TP53":1,
"Central Neck Dissection":1,
"Lymph Node Ratio":1,
"Adjuvant endocrine therapy":1,
"Leuprorelin acetate":1,
"Luteinizing hormone-releasing hormone agonist":1,
"Premenopausal endocrine-responsive breast cancer":1,
"Quality of life":1,
"anterolateral thigh (ALT) flap":1,
"esophagus and voice reconstruction":1,
"free ileocolon flap":1,
"total pharyngolaryngectomy":1,
"iodine radioisotopes":1,
"saliva":1,
"salivary glands":1,
"xerostomia":2,
"CT":1,
"PET":1,
"PET/CT":1,
"findings":1,
"head and neck cancer":2,
"imaging":2,
"incidental":1,
"Histologic mimics":1,
"Metastatic neoplasms":1,
"Microscopic simulants of metastasis":1,
"anxiety":1,
"clinical guidelines":1,
"interdisciplinary care":1,
"screening for distress":1,
"symptom management":1,
"Asymptomatic":1,
"Parathyroid carcinoma":1,
"Primary hyperparathyroidism":1,
"Symptomatic":1,
"MET proto-oncogene":1,
"RET proto-oncogene":1,
"familial medullary thyroid cancer":1,
"medullary thyroid cancer":2,
"whole exome sequencing":2,
"HRPT2/CDC73":1,
"hyperparathyroidism":1,
"hyperparathyroidism-jaw tumor syndrome":1,
"younger age":1,
"Intramedullary metastasis":1,
"Spinal cord tumour":1,
"accuracy":2,
"indeterminate thyroid cytology":1,
"meta-analysis":3,
"molecular diagnostics":1,
"cytological finding":1,
"familial thyroid cancer":1,
"family history":1,
"thyroid disease":4,
"artificial intelligence":1,
"artificial neural network":1,
"follicular adenoma":1,
"follicular carcinoma":1,
"Lenvatinib":2,
"Radioiodine therapy":1,
"Tyrosine kinase inhibitor":2,
"carbon dioxide embolism":1,
"endoscopic thyroidectomy":1,
"remote access thyroidectomy":1,
"robotic thyroidectomy":1,
"transoral thyroidectomy":1,
"PTEN hamartoma tumor syndrome (PHTS)":1,
"Screening":1,
"Adolescents":1,
"Adults":1,
"Childhood cancer survivors":1,
"Late effects":1,
"cell cycle":2,
"mitogen-activated protein kinase pathway":1,
"solute carrier family 35 member F2":1,
"tumorigenesis":2,
"Adequacy":1,
"Liquid-based cytology":1,
"Needle gauge":1,
"cytology":3,
"diagnosis":2,
"molecular testing":2,
"Cancer stem-like cells":1,
"Epithelial to mesenchymal transition":1,
"In situ hybridization":1,
"Long non-coding RNAs":1,
"Diffuse uptake":1,
"FDG-PET":1,
"Focal uptake":1,
"Branchial cleft cyst":1,
"Lateral neck":1,
"Malignancy":4,
"Papillary thyroid carcinoma (PTC)":1,
"Squamous cell carcinoma (SCC)":1,
"cabozantinib":1,
"renal cell carcinoma":1,
"H19":1,
"Long noncoding RNA":1,
"radiotherapy":2,
"targeted therapy":2,
"treatment protocol":1,
"complications":1,
"cosmetic effect":1,
"transoral endoscopic thyroidectomy":1,
"circulating miRNA":1,
"metastases":1,
"miR-375":1,
"prognostic biomarker":1,
"Risk stratification":1,
"Strain value":1,
"TIRADS":1,
"Thyroid ultrasound":1,
"Visual elasticity scores":1,
"CDK4":1,
"CDK6":1,
"LEE011":1,
"Retinoblastoma protein (RB)":1,
"ASCT2":1,
"boramino acid":1,
"cancer imaging":1,
"positron emission tomography":1,
"Differentiated thyroid carcinoma":4,
"Intracranial metastases":1,
"Neurosurgery":1,
"Whole brain radiotherapy":1,
"EMT":1,
"angiogenesis":3,
"miRNA-205":1,
"FTC":1,
"TRAIL resistance":1,
"apoptosis":4,
"cIAP1/2":1,
"GAS8-AS1":1,
"autophagy":1,
"lncRNA":1,
"DICER1":1,
"endocrine tumors":1,
"mutation":2,
"neoplasms":1,
"pathology":2,
"AFAP1-AS1":1,
"Cell growth":1,
"Migration":1,
"precancerous conditions":1,
"30 mCi":1,
"Japan":1,
"Radioactive iodine ablation":1,
"liquid biopsy":1,
"peripheral blood":1,
"prognosis":6,
"programmed death-ligand 1":1,
"lateral cervical lymph node metastasis":1,
"prophylactic lymph node dissection":1,
"sporadic medullary thyroid carcinoma":1,
"progression-free survival":1,
"radioactive iodine refractory":1,
"real-world clinical practice":1,
"sorafenib":1,
"GEC testing":1,
"Indeterminate FNAB":1,
"gene fusions and mutations":1,
"next-generation sequencing":1,
"Copper-64":1,
"Immuno-PET":1,
"Platelet-derived growth factor receptor":1,
"BRAF":2,
"Follicular variant":1,
"calcium deposition":1,
"hyalinized trabecular tumor":1,
"thyroid tumor":1,
"von Kossa stain":1,
"endocrine neoplasm":1,
"incidental findings":1,
"IDO1":1,
"Immune checkpoint":1,
"Immuno-oncology":1,
"Indoleamine 2,3-dioxygenase 1":1,
"PD-L1":1,
"PD1":1,
"Programmed cell death ligand 1":2,
"SEER":3,
"follicular thyroid cancer":1,
"tumor size":1,
"Aggressive variants":1,
"Autoimmunity":1,
"Thyrotrophin":1,
"Differential diagnosis":1,
"Fine needle aspiration cytology":1,
"Follicular neoplasm":1,
"biomarkers":1,
"encapsulated PTC":1,
"follicular variant of PTC":1,
"miRNA":1,
"BRAFV600E":1,
"biomarker":1,
"circulation tumor cells":1,
"Sanger sequencing":2,
"informative marker":1,
"multiple endocrine neoplasia type 2":1,
"preimplantation genetic diagnosis":1,
"targeted sequencing":1,
"Desmoplasia":1,
"Node":1,
"Immunohistochemistry":4,
"Fine needle aspiration (FNA)":1,
"Indeterminate follicular proliferation":1,
"Extranodal extension":1,
"Lymph node size":1,
"Size stratification":1,
"DNA repair":1,
"ionizing radiation":1,
"radiosensitivity":1,
"thyroid cells":1,
"outcomes":1,
"presentation":1,
"treatment":1,
"trends":1,
"Treatment de-escalation":1,
"EPR effect":1,
"HPMA":1,
"Iodine-131":1,
"RAFT":1,
"Walker 256 mammary carcinoma":1,
"RAI-resistant":1,
"Recurrence risk":1,
"TERT promoter mutations":1,
"ETV6/NTRK3":1,
"gene alteration":1,
"pediatric thyroid cancer":1,
"sporadic":1,
"Dose-volume parameters":1,
"HNSCC":1,
"Radiation-induced HT":1,
"TSH":3,
"Biopsy, fine-needle":1,
"Hashimoto disease":1,
"Thyroid cancer, papillary":1,
"Warthin-like variant":1,
"Squamous differentiation":1,
"Carcinoma de células de Hürthle":1,
"Carcinoma folicular de tiroides":1,
"Disease-free survival":1,
"Supervivencia libre de enfermedad":1,
"Tiroidectomía":1,
"B-Raf proto-oncogene":1,
"molecular biology":1,
"rat sarcoma":1,
"serine/threonine kinase":1,
"telomerase reverse transcriptase promoter":1,
"BRCA1":1,
"BRCA2":1,
"Chinese population":1,
"breast neoplasms":2,
"clinic-pathological":1,
"BTG2":1,
"PRMT5":1,
"Prognostic marker":1,
"hepatocellular carcinoma":1,
"body weight":1,
"endocrine surgery":1,
"general surgery":1,
"prognostic significance":1,
"Adenocarcinoma":1,
"Bone neoplasm":1,
"Follicular":1,
"Cancer thyroïdien":1,
"Goitre ovarien":1,
"Ovarian teratoma":1,
"Struma ovarii":1,
"Tératome ovarien":1,
"T cytotoxic 17":1,
"T helper 17 cells":1,
"radioactive iodine-131":1,
"regulatory T cells":1,
"NRAS":1,
"Organoid":1,
"Thyroid cancer model":1,
"p53":1,
"radioiodine":1,
"salivary hypofunction":1,
"Histology":1,
"Low-grade malignant endolymphatic sac tumor":1,
"VHL syndrome":1,
"LncRNAs":1,
"tyrosine kinase inhibitors":1,
"Lymph nodes":1,
"Mortality":5,
"TNM staging":1,
"Communication":1,
"Decision making":1,
"Overdiagnosis":1,
"Overtreatment":1,
"Treatment preferences":1,
"Coarse calcification":1,
"Computed tomography histogram":1,
"Race":1,
"medications":1,
"oral lichen planus":1,
"oral lichenoid drug reaction":1,
"oral lichenoid lesion":1,
"systemic disease":1,
"Predictive model":1,
"Eudorcas thomsonii":1,
"Thomson's gazelle":1,
"histopathology":2,
"thyroid transcription factor":1,
"FDG PET/CT":1,
"Fluorine-18-fluorodeoxyglucose":1,
"Metabolic tumor volume":1,
"Thyroid incidentaloma":1,
"Total lesion glycolysis":1,
"South Korea":1,
"detection bias":1,
"nuclear power plant":1,
"Extra-pulmonary malignancy":1,
"Interventional bronchoscopy":1,
"Malignant central airway obstruction":1,
"ICCC":1,
"age-standardized incidence rate":1,
"annual percent change":1,
"childhood cancer":1,
"evidence synthesis":1,
"indirect treatment comparison":1,
"number needed to treat":1,
"Activating mutation":1,
"Fibrous dysplasia":1,
"GNAS":1,
"Heterotrimeric Gs protein":1,
"Intraductal papillary mucinous neoplasm":1,
"McCune Albright Syndrome":1,
"Neoplasm":1,
"Over diagnosis":1,
"PTMC":1,
"Pathological classifications":1,
"Autoimmune diseases":1,
"Diabetes":1,
"Inflammation":1,
"Radiation":2,
"immune-related adverse event":1,
"immunotherapy":2,
"lung cancer":1,
"myositis":1,
"nivolumab":1,
"Angioinvasive FTC":1,
"Developing country":1,
"Minimally invasive FTC":1,
"Widely invasive FTC":1,
"Hypopharynx":1,
"Larynx":1,
"Lymphnode":1,
"Nodal metastasis":1,
"Small-sized thyroid carcinoma":1,
"Calcitonin":1,
"RET":1,
"Metastatic FTC":1,
"Occult primary malignancy":1,
"Occult thyroid carcinoma":1,
"IL13Rα2 siRNA":1,
"columnar cell":1,
"disease-specific survival":1,
"distant metastasis":1,
"encapsulated variant":1,
"external beam radiotherapy":1,
"Thyroid cancer and age":1,
"Thyroid cancer staging":1,
"laser":1,
"post-operative scar":1,
"scar":1,
"lymph node aspirate for thyroglobulin (LN-FNA-Tg)":1,
"malignant sonographic features of lymph nodes":1,
"Central cervical lymph node":1,
"Neoplasms metastasis, lymph node":1,
"Ultrasound examination":1,
"Bethesda":1,
"TI-RADS":1,
"risk of malignancy":1,
"Waddington landscape":1,
"developmental history":1,
"non-small cell lung cancers":1,
"transdifferentiation":1,
"tumor heterogeneity":1,
"tumor plasticity":1,
"Myxoid liposarcoma":1,
"mucinous carcinoma":1,
"primary thyroid cancer":1,
"signet-ring-cell differentiation":1,
"8505c cells":1,
"Baicalein":1,
"Combination therapy":1,
"Docetaxel":1,
"Thyroid carcinoma, anaplastic":1,
"adrenal disorders":1,
"endocrine cancer":1,
"surveillance":2,
"total thyroidectomy":2,
"Chronic lymphocytic thyroiditis":1,
"Disease persistence":1,
"CRABP2":1,
"anaplastic thyroid cancer":1,
"drug resistance":1,
"resveratrol":1,
"retinoic acid":1,
"Long noncoding RNAs (lncRNAs)":1,
"Papillary thyroid cancer (PTC)":1,
"breast tumours":1,
"preventive medicine":1,
"Immunohistochemical expression":1,
"Macrophages":1,
"TGF-β pathway":1,
"interferon γ":1,
"interleukin 21":1,
"circulating cell-free DNA":1,
"2018":1,
"ACTH":1,
"Acromegaly":1,
"Adult":1,
"Breathing difficulties":1,
"CT scan":1,
"Desmopressin":1,
"Diabetes insipidus":1,
"Face - coarse features":1,
"Fatigue":1,
"Fine needle aspiration biopsy":1,
"GH":1,
"GH suppression":1,
"Glucocorticoids":1,
"Glucose tolerance (oral)":1,
"Gonadotrophins":1,
"Gonadotropins":1,
"Hands - enlargement":1,
"Headache":1,
"Hydrocortisone":1,
"Hypergonadotropic hypogonadism":1,
"Hypogonadism":1,
"IGF1":1,
"Lanreotide":1,
"Levothyroxine":1,
"MRI":1,
"Male":1,
"March":1,
"PET scan":1,
"Pituitary":1,
"Prolactin":1,
"Resection of tumour":1,
"Somatostatin analogues":1,
"Synaptophysin":1,
"Testosterone":1,
"Transsphenoidal surgery":1,
"Unique/unexpected symptoms or presentations of a disease":1,
"United Kingdom":1,
"Vision - acuity reduction":1,
"Visual field assessment":1,
"Visual impairment":1,
"White":1,
"X-ray":1,
"Multiple primary neoplasms":1,
"AMP kinase":1,
"Warburg effect":1,
"glutaminolysis":1,
"glycolysis":1,
"hexokinase":1,
"hypoxia-inducible factor":1,
"mammalian target of rapamycin protein":1,
"18F-FDG PET/CT":1,
"99mTc-MIBI":1,
"mitochondria":1,
"sclerosing pneumocytoma":1,
"Insulin Resistance":1,
"Airway stents":1,
"airway obstruction/therapy":1,
"bronchi/pathology":1,
"prosthesis design":1,
"prosthesis implantation":1,
"tracheal neoplasms/therapy":1,
"PDX":1,
"hypoxia":1,
"photoacoustic imaging":1,
"endometriosis associated ovarian carcinoma":1,
"ovarian endometriosis":1,
"prediction of malignant transformation":1,
"different diseases":1,
"sensitivity":1,
"sonoelastography":1,
"specificity":1,
"NF-κB":1,
"TIPE":1,
"TNF-α":1,
"TNFAIP8":1,
"Cali":1,
"Cancer registry":1,
"Colombia":1,
"methods":1,
"Ecuador":1,
"Latin America":1,
"Bucaramanga":1,
"records as subject":1,
"deferred intervention":1,
"low risk thyroid cancer":1,
"thyroid lobectomy":1,
"Thyroid metastasis":1,
"tonsil squamous cell carcinoma":1,
"HOXC6":1,
"Linc00339":1,
"MiR-377-3p":1,
"progression":1,
"triple-negative breast cancer (TNBC)":1,
"Breast cancer":1,
"Mitochondrial targeting":1,
"TPA":1,
"TR3":1,
"FVPTC":1,
"AUS":1,
"Bethesda classification":1,
"FLUS":1,
"Indeterminate":1,
"Molecular":1,
"glucose metabolism":1,
"healthspan":1,
"hyperthyroidism":1,
"hypothyroidism":1,
"lifespan":1,
"thyroid hormones":1,
"Mena":1,
"overexpression":1            };
            var data = [];
            for (var name in keywords) {
                data.push({
                    name: name,
                    value: Math.sqrt(keywords[name])
                })
            }
            var maskImage = new Image();
            var option = {
	             title: {
                text: '2018年3月论文keyword词云'
            },
                series: [ {
                    type: 'wordCloud',
                    sizeRange: [15, 100],
                    rotationRange: [-90, 90],
                    rotationStep: 45,
                    gridSize: 2,
                    shape: 'pentagon',
                    maskImage: maskImage,
                    drawOutOfBound: false,
                    textStyle: {
                        normal: {
                            color: function () {
                                return 'rgb(' + [
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160)
                                ].join(',') + ')';
                            }
                        },
                        emphasis: {
                            color: 'red'
                        }
                    },
                    data: data.sort(function (a, b) {
                        return b.value  - a.value;
                    })
                } ]
            };
            maskImage.onload = function () {
                option.series[0].maskImage
                chart.setOption(option);
            }
            maskImage.src = 'data:image/png;base64,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';
            window.onresize = function () {
                chart.resize();
            }
        </script>
    </body>
</html>
